Key result
MicroRNAs are involved in the pathogenesis of diabetes mellitus and its cardiovascular complications, potentially serving as early biomarkers and therapeutic agents.
This review highlights the potential of microRNAs as early biomarkers and therapeutic targets for cardiovascular disease in patients with diabetes mellitus.
Does not support clinical adoption of microRNA assays; leaves open their biomarker or therapeutic utility pending prospective trials.
Diabetes mellitus (DM) is a complex metabolic disorder characterized by low insulin production/secretion by pancreatic beta cells and/or low responsiveness by insulin target tissues MicroRNAs have been associated with DM, but it is not clear whether this is a cause or an effect of metabolic abnormalities related to DM. In the hyperglycemic environment miRNAs are in involved in multiple stages of cardiovascular disease development and progression. In diabetic patients with cardiovascular disease miRNAs could potentially serve as early biomarkers for diagnosis and as therapeutic agents. The current review focuses on the involvement of miRNAs in molecular mechanisms underlying the pathogenesis of DM and its cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Briasoulis et al. (2013) conducted a review in Diabetes mellitus and cardiovascular disease. MicroRNAs was evaluated. MicroRNAs are involved in the pathogenesis of diabetes mellitus and its cardiovascular complications, potentially serving as early biomarkers and therapeutic agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: